Gilead Sciences' (GILD) Antiviral Drug Remdesivir Flops in First trial - FT
Go back to Gilead Sciences' (GILD) Antiviral Drug Remdesivir Flops in First trial - FT| Gilead Sciences (NASDAQ: GILD) | Delayed: 125.10 +1.34 (1.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.76 | 52 Week High | $108.63 | |||
| Open | $124.30 | 52 Week Low | $71.39 | |||
| Day High | $125.14 | P/E | 69.12 | |||
| Day Low | $123.00 | EPS | $1.81 | |||
| Volume | 3,312,680 | |||||
| S&P DEP RECEIPTS (NYSE: SPY) | Delayed: 745.27 -1.47 (0.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $746.74 | 52 Week High | $219.60 | |||
| Open | $747.70 | 52 Week Low | $181.02 | |||
| Day High | $750.18 | P/E | N/A | |||
| Day Low | $743.15 | EPS | $0.00 | |||
| Volume | 24,772,254 | |||||
